CC #2
- more product launches after 3 years (in addition to the initial 60)
- new pipeline = developments of their own portfolio + changes to strengths of existing products to suit the developments of patients
- AMCo performs "very strongly"; use cashflow to service obligations
- "Brexit" wont affect CXR business; no impact to supply chain
- The AMCo beat was not due to seasonality; no seasonality to AMCo
- No pushback so far on pricing from the US; think its mostly a political issue; CXR doesn't hold patients hostage with price; no issue in that regard